2003
Addition of sertraline to other therapies to reduce dialysis‐associated hypotension
BREWSTER UC, CIAMPI MA, ABU‐ALFA A, PERAZELLA MA. Addition of sertraline to other therapies to reduce dialysis‐associated hypotension. Nephrology 2003, 8: 296-301. PMID: 15012700, DOI: 10.1111/j.1440-1797.2003.00216.x.Peer-Reviewed Original ResearchConceptsDialysis-associated hypotensionCentral blood volumePeripheral vascular resistanceBlood pressureCardiac outputBlood volumeEnd-stage renal disease patientsInitiation of dialysisRenal disease patientsDiastolic blood pressureSystolic blood pressureEffects of sertralineTermination of dialysisAddition of sertralineUltrasound dilution techniqueVascular resistanceArterial pressureHaemodynamic measurementsDisease patientsPatientsControl phaseSertralineTherapyDialysisHypotension
2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors